Title:
Promising drug targets and associated therapeutic interventions in Parkinson's disease

Simple item page
dc.contributor.authorSachchida Nand Rai
dc.contributor.authorPayal Singh
dc.contributor.authorRitu Varshney
dc.contributor.authorVivek K. Chaturvedi
dc.contributor.authorEmanuel Vamanu
dc.contributor.authorM.P. Singh
dc.contributor.authorBrijesh Kumar Singh
dc.date.accessioned2026-02-07T10:38:53Z
dc.date.issued2021
dc.description.abstractParkinson's disease (PD) is one of the most debilitating brain diseases. Despite the availability of symptomatic treatments, response towards the health of PD patients remains scarce. To fulfil the medical needs of the PD patients, an efficacious and etiological treatment is required. In this review, we have compiled the information covering limitations of current therapeutic options in PD, novel drug targets for PD, and finally, the role of some critical beneficial natural products to control the progression of PD. © 2021 Wolters Kluwer Medknow Publications. All rights reserved.
dc.identifier.doi10.4103/1673-5374.306066
dc.identifier.issn16735374
dc.identifier.urihttps://doi.org/10.4103/1673-5374.306066
dc.identifier.urihttps://dl.bhu.ac.in/bhuir/handle/123456789/37381
dc.publisherWolters Kluwer Medknow Publications
dc.subjectdopamine
dc.subjectepigenetics
dc.subjectgene therapies
dc.subjectglutamate receptor
dc.subjectlevodopa
dc.subjectmolecular chaperones
dc.subjectmonoamine oxidase B
dc.subjectmucuna alpha-synuclein
dc.subjectParkinson's disease
dc.subjectstriatum
dc.subjectsubstantia nigra
dc.titlePromising drug targets and associated therapeutic interventions in Parkinson's disease
dc.typePublication
dspace.entity.typeReview

Files

Collections

2021
An Initiative by BHU – Central Library
Powered by Dspace